Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.
50 patients for re-intervention of hip prosthesis with friction couples of: ceramic-on-ceramic or metal-on-metal
(25 patients by group)

Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.
50 patients for re-intervention of hip prosthesis of stainless steel ball.

Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.
50 inpatient subjects for re-intervention of knee prosthesis polyethylene-on-metal.

Autopsy: 80 dead patients IMD holders will be autopsied.

Autopsy: dead patients non-IMD holders autopsied, 30 subjects in this arm.

Before the initial prosthesis surgery: 30 patients Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections will be done

Biomarker

Systemic Inflammation

All inpatient subjects: following samples will be collected during hospitalization:
Twice blood and urine collections:
at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;
at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter

Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections

Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.

Autopsy

Service de Chirurgie orthopédique, Hôpital Raymond Poincaré

Study of Systemic Impact of Trace Elements Release by Implantable Medical Devices. Identification of Biomarkers of Systemic Inflammation

Demonstration of systemic inflammation induced by the trace elements existing in IMD with blood and tissue criteria:
1/ A measure by flow cytometry to identify hyperactivated circulating mononuclear cells (macrophages, dendritic cells, T and B lymphocytes), in contact with trace element nanoparticles and thus, to highlight an immunophenotype of this inflammation.

Demonstration of systemic inflammation induced by the trace elements existing in IMD with blood and tissue criteria:
2/ A measure by multiplex LuminexTM (Bio-plex ProTM human inflammation panel, Bio-rad) to identify specific circulating proteins such as TNF, IFN, cytokines, chemokines, metalloproteins, related to activation of the cells of inflammation throughout release of particles and salting out of trace elements by IMD

Demonstration of systemic inflammation induced by the trace elements existing in IMD with blood and tissue criteria:
- 3/ A macroscopic study of organs to determine the possible presence of tumor foci

Demonstration of systemic inflammation induced by the trace elements existing in IMD with blood and tissue criteria:
- 4/ Cytopathological analysis on slides, after sampling, fixation, inclusion and staining with hematoxylin-eosin-saffron to evaluate semi-quantitatively the type of inflammation (chronic if mononuclear cells or acute if neutrophils) and degree according to the number of inflammatory cells

Trace elements dosing in liquids and tissue by high resolution ICP mass spectrometry in studied sub-population (autopsied IMD holder and non-holder dead subjects, IMD holder living patients with inflammatory reaction and will undergo re-intervention) and in each analyzed material in non-mineralized form, in order to determinate concentrations of free trace elements and after full mineralization to determinate the concentrations of trace elements in nanoparticle form.

Comparison of concentrations of 40 analyzed trace elements in different materials, depending on the groups.

Assistance Publique - Hôpitaux de Paris

those with a diagnosis of coronary artery disease having been hospitalized for a cardiac event. The intervention is six-month interval of exercise .

Metabolic Syndrome patients are defined by having Systolic Blood Pressure (SBP)>130 and/or Diastolic Blood Pressure (DBP)>85 mmHg and any two of the following criteria: Abdominal obesity (waist circumference >102cm in males;>88cm in females), Fasting triglycerides > 1.695 mmol/L, Low HDL cholesterol: Males < 1.04 mmol/L; Females < 1.29 mmol/L, Fasting glucose >5.60 mmol/L. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.

Control individuals will have no diagnosis of cardiac, vascular, metabolic, inflammatory or neurological disease, and have not been on any medication for such conditions in the past 12 months. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.

Cardiovascular Disease

exercise

the University of Western Ontario

Cerebrovascular Outcomes in Ischemic Heart Disease

Cerebrovascular Outcomes in Ischemic Heart Disease Patients Undergoing Cardiac Rehabilitation

This will be measured first by the change in blood flow velocity through the middle cerebral artery in response to the 5% CO2/95% O2 challenge and a sit-to-stand manoeuvre. Measures will be made using transcranial Doppler. Subsequently, the diameter of the middle cerebral artery will be measured with MRI T2 sequences (time of flight) at 7Tesla.
Multiple measurements will be aggregated to arrive at one reported value of cerebrovascular reactivity to carbon dioxide.

These will be made with pen-and paper questionnaires identified above.

This is measured from the MRI T1 anatomical and FLAIR sequences.
Multiple measurements will be aggregated to scientifically examine the association between (cardio)vascular disease, blood supply to the brain, and cerebrovascular endothelial activation. These measurements will allow us to investigate the impact of exercise rehabilitation on brain vascularization, cerebrovascular endothelial function and blood flow control.

will be measured using multiplex and ELISA technology,

will be assessed using ultrasound imaging analysis of intima-media thickness (Carotid artery) and the flow-mediated dilation of the brachial artery.

Kevin Shoemaker

Dr. Kevin Shoemaker

Western University, Canada

Lawson Health Research Institute

10 patients with hemochromatosis treated with Deferasirox

10 patients with hemochromatosis treated with venesection

20 patients with myelodysplastic syndrome treated with Deferasirox

10 healthy control persons to assess the normal level of investigational blood tests.

Hemochromatosis

Myelodysplastic Syndromes

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months

Deferasirox

Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.

Venesection

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.

Haukeland University Hospital, Clinical Trial Unit

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.

tungsten/inflammation

Study of Systemic Impact of Trace Elements Release by Implantable Medical Devices. Identification of Biomarkers of Systemic Inflammation

Cerebrovascular Outcomes in Ischemic Heart Disease

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

科学に裏打ちされた最も完全な薬草データベース